Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104.08 USD | -1.77% |
|
+6.16% | +12.68% |
02-14 | US Equity Indexes Rise in Week Amid Tariff Tumult, Hot Inflation, Fed on Pause | MT |
02-14 | Gilead Sciences Insider Sold Shares Worth $14,073,241, According to a Recent SEC Filing | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development and Commercialization of Innovative Medicines | 22.45B | 24.69B | 27.3B | 27.28B | 27.12B | |||||
Total Assets | 61.63B | 68.41B | 67.95B | 63.17B | 62.12B | |||||
Interest Expense | -995M | -984M | -1B | -935M | -944M | |||||
Income Tax Expense | -204M | 1.58B | 2.08B | 1.25B | 1.25B | |||||
CAPEX | -825M | -650M | -579M | -728M | -585M | |||||
EBT | 5.16B | 1.67B | 8.28B | 5.81B | 6.86B | |||||
D&A | 1.4B | 1.48B | 2.05B | 2.1B | 2.69B | |||||
Operating Income | 4.29B | 4.07B | 9.92B | 7.33B | 7.6B | |||||
Net Income | 5.39B | 123M | 6.22B | 4.59B | 5.66B |
Geographical Revenue Distribution History
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
United States | 16.64B | 18.22B | 19.27B | 18.88B | 19.44B | |||||
Total Assets | 3.5B | 3.8B | 4.1B | 4.5B | 4.69B | |||||
Europe | 3.81B | 4.14B | 4.87B | 4.47B | 4.31B | |||||
Total Assets | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Rest of World | 1.99B | 2.34B | 3.16B | 3.93B | 3.37B | |||||
Total Assets | 791M | 897M | 963M | 973M | 626M | |||||
Japan | - | - | - | - | - |
- Stock Market
- Equities
- GILD Stock
- Financials Gilead Sciences, Inc.
- Business Segments

MarketScreener is also available in this country: United States.
Switch edition